Major award for world-leaders in melanoma research

Major award for world-leaders in melanoma research

9 November 2018

Melanoma Institute Australia’s (MIA) Co-Medical Directors have won the prestigious GSK Award for Research Excellence at Research Australia’s Health and Medical Research Awards.

Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.

Professor Long and Professor Scolyer believe that with the advancement of both immune- and targeted therapies (those treatments that utilise patients’ immune systems to fight cancer or alter the function of specific genes to arrest the growth of cancer) we are now realistically looking towards achieving zero deaths from melanoma within their lifetimes.

“As Australians, we’re proud of the success our country has had in leading the fight against melanoma but there’s still much more to do and discover. There’s a critical need to better understand why some melanomas develop so we can improve prevention and treatment,” said Professor Scolyer.

“While we do have these breakthrough therapies, there are still a group of patients who are resistant,” added Professor Long. “We’re starting to understand why patients develop resistance – and if we can tackle this by individualising and targeting therapy, we will impact not only melanoma but all cancers.”

Professor Long and Professor Scolyer said that winning the GSK Award for Research Excellence highlights the importance of recognising Australian successes in the research space, and is testament to the power of collaboration that MIA strives to emphasise in its work.

“Collaboration is vital for big research steps and gains. For us, this award recognises not only our team, but the collaborative efforts of our predecessors, colleagues, industry and patients,” said Professor Long. “We stand on the shoulders of others’ foresight and hard work, as well as the generosity of Australian patients whose participation in clinical trials is critical to scientific discovery.”

“It’s important that Australian science and research success is celebrated, and we are grateful to be a part of that story. We are honoured and humbled to have received this award as we, and our team, work hard to impact the lives of patients all over the world,” said Professor Scolyer.

Dr. Andrew Weekes, Medical Director of GSK, said; “The work of Professors Long and Scolyer is an outstanding example of how home-grown innovation and collaboration can impact the lives of patients around the world. We are honoured to recognise their achievements and support research which could underpin further discoveries and better outcomes for patients.”

The GSK Award for Research Excellence is one of the most prestigious awards available to the Australian medical research community. It has been awarded since 1980 to recognise outstanding achievements in medical research with potential importance to human health.

The GSK Award comes just a week after MIA’s Co-Medical Directors, and their fellow researchers Associate Professor Alex Menzies and Associate Professor Anne Cust, received top awards at the NSW Premier’s Awards for Outstanding Cancer Research.

The Face of Melanoma March
28 Jan 2016

The Face of Melanoma March

Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.

Q&A With An Expert: Dermatologist
28 Jan 2016

Q&A With An Expert: Dermatologist

MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen. 

New figures show melanoma most common cancer in young Queenslanders
08 Jan 2016

New figures show melanoma most common cancer in young Queenslanders

Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.

5 minutes with Associate Professor Georgina Long
17 Dec 2015

5 minutes with Associate Professor Georgina Long

As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.

Watch Your Mate's Back: helping young Australians recognise melanoma
30 Nov 2015

Watch Your Mate's Back: helping young Australians recognise melanoma

MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same. 

Your Guide to Early Melanoma patient information packs
21 Oct 2015

Your Guide to Early Melanoma patient information packs

Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.   

Clinicians invited to MIA's 'World Round Up' event
21 Oct 2015

Clinicians invited to MIA's 'World Round Up' event

Special Event to share advances in diagnosis and treatment of both early and late stage melanoma

Melanoma landmark study to develop personalised cancer treatment
26 Aug 2015

Melanoma landmark study to help further develop personalised cancer treatment

MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma 

Sunrise features inspiring story of MIA patient
10 Aug 2015

Sunrise features inspiring story of MIA patient

Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week. 

Leading researchers honoured for global contribution to science and innovation
16 Jul 2015

Leading researchers honoured for global contribution to science and innovation

Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.

MIA welcomes ground-breaking new PBS melanoma treatment
03 Jul 2015

MIA welcomes ground-breaking new PBS melanoma treatment

New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).

MIA contributes to major research breakthrough which pioneers a new way of treating cancer
01 Jun 2015

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.

Q&A with our Clinical Research Fellow
26 May 2015

Q&A with our Clinical Research Fellow

We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam

International Clinical Trials Day marked
20 May 2015

International Clinical Trials Day marked

Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research. 

5 minutes with Practice Manager Sherrie D'Souza
15 May 2015

5 minutes with Practice Manager Sherrie D'Souza

We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role. 

Associate Professor Georgina Long has won the InStyle Women In Style Award
14 May 2015

Associate Professor Georgina Long has won the InStyle Women In Style Award

Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category. 

The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Professor Thompson made an honorary member of the American Surgical Association
01 May 2015

Professor Thompson made an honorary member of the American Surgical Association

The Association's members include prominent surgeons from around the world. 

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 Apr 2015

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers. 

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 Apr 2015

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA

Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.